Ivanova, Elizaveta,
Asadullina, Dilara,
Gilyazova, Gulshat,
Rakhimov, Radmir,
Izmailov, Adel,
Pavlov, Valentin,
Khusnutdinova, Elza,
Gilyazova, Irina (2023) renal cell carcinoma (ccRCC) treatment. However, the response to
therapy among patients
varies greatly
Wang, CL,
Zheng, BJ,
Gareev, I,
Beylerli, O,
Gu, Y,
Xu, SC,
Ji, ZY,
Wu, P,
Shi, HZ (2021) salvage
therapy for AIS patients after CEA is necessary. In this study,we report three patients in our
therapy in the development of these cerebrovascular complications, which can occur at various stages
Afolabi, A.,
Mustafina, I.,
Zhao, L.,
Li, L.,
Sun, R.,
Hu, S.,
Zhang, S.,
Jia, H.,
Guilio, G.,
Yu, B. (2018) of plaque progression to statin
therapy. Background: Previous studies showed that the presence of spotty
Paar, V.,
Jirak, P.,
Larbig, R.,
Zagidullin, N.S.,
Brandt, M.C.,
Lichtenauer, M.,
Hoppe, U.C.,
Motloch, L.J. (2019) . We highlight the therapeutic potential of gene
therapy as a novel and innovative approach for future
Nasyrova, Regina F.,
Khasanova, Aiperi K.,
Altynbekov, Kuanysh S.,
Asadullin, Azat R.,
Markina, Ekaterina A.,
Gayduk, Arseny J.,
Shipulin, German A.,
Petrova, Marina M.,
Shnayder, Natalia A. (2022) the search for new therapeutic strategies for a disease-modifying
therapy for treatment-resistant Sch (TRS
Tyurin, Anton V.,
Akhiyarova, Karina E.,
Valishin, Damir A.,
Sadretdinova, Lidiya D.,
Khusainova, Leonora N.,
Zagidullin, Naufal S.,
Gantseva, Khalida K.,
Pavlov, Valentin N. (2022) The objective of our study was the analysis of using immunosuppressive
therapy in patients